Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q16647
UPID:
PTGIS_HUMAN
Alternative names:
Hydroperoxy icosatetraenoate dehydratase; Prostaglandin I2 synthase
Alternative UPACC:
Q16647; Q3MII8; Q9HAX2; Q9HAX3; Q9HAX4
Background:
Prostacyclin synthase, also known as Hydroperoxy icosatetraenoate dehydratase, plays a pivotal role in the biosynthesis and metabolism of eicosanoids. It specifically catalyzes the isomerization of prostaglandin H2 to prostacyclin, a key mediator of vasodilation and inhibitor of platelet aggregation. This enzyme also exhibits dehydratase activity towards hydroperoxyeicosatetraenoates, particularly (15S)-HPETE.
Therapeutic significance:
Given its crucial role in regulating blood pressure and preventing blood clot formation, Prostacyclin synthase is directly linked to essential hypertension. Understanding the role of Prostacyclin synthase could open doors to potential therapeutic strategies for managing hypertension and cardiovascular diseases.